A new mechanism of methylprednisolone and other corticosteroids action demonstrated in vitro: Inhibition of a proteinase (calpain) prevents myelin and cytoskeletal protein degradation

Brain Research

Volumn 748, Issue 1-2, 1997, Pages 205-210

  Banik, Naren L ^a   Matzelle, Denise ^a   Terry, Elaine ^a   Hogan, Edward L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

calpain; corticosteroid; inhibitor; myelin basic protein; neurofilament; neuroprotection; spinal cord

Indexed keywords

CALPAIN; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; INDOMETACIN; KETOROLAC; MEPREDNISONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYELIN BASIC PROTEIN; NEUROPROTECTIVE AGENT; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; SUCCINIC ACID;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SPINAL CORD; TISSUE HOMOGENATE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CALPAIN; CATHEPSIN B; CYTOSKELETAL PROTEINS; METHYLPREDNISOLONE; MYELIN BASIC PROTEINS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 0031049642     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01302-9     Document Type: Article

References (48)

1. Azaryan, A., Banay-Schwartz, M. and Lajtha, A., The presence of ATP/ubiquitin-dependent proteinase complex in bovine brain, Neurochem. Res., 14 (1991) 995-1001.
2. Balentine, J.D., Pathology of experimental spinal cord trauma. II. Ultrastructure of axon and myelin, Lab. Invest., 39 (1978) 254-266.
3. Banay-Schwartz, M., DeGuzman, T., Palkovits, M. and Lajtha, A., Calpain activity in adult and aged human brain regions, Neurochem. Res., 19 (1994) 563-567.
4. Banik, N.L., The degradation of myelin basic protein by serum proteinase in experimental allergic encephalomyelitis and control rats, Neurosci. Lett., 11 (1979) 307-312.
5. Banik, N.L., Powers, J.M. and Hogan, E.L., The effect of spinal cord trauma on myelin, J. Neuropathol. Exp. Neurol., 39 (1980) 232-244.
6. Banik, N.L., Hogan, E.L., Powers, J.M. and Whetstine, L.J., Degradation of neurofilament proteins in spinal cord injury, Neurochem. Res., 7 (1982) 1465-1475.
7. Banik, N.L., Smith, K.P., Powers, J.M. and Hogan, E.L., Proteolytic enzymes in spinal cord injury, J. Neurol. Sci., 73 (1986) 245-256.
8. Banik, N.L., Chakrabarti, A.K. and Hogan, E.L., Role of calcium-activated neutral proteinase in myelin: its role and function. In R. Martenson (Ed.), Myelin, Biology and Chemistry, CRC Press, Boca Raton, FL, 1992, pp. 571-597.
9. Banik, N.L., Pathogenesis of myelin breakdown in demyelinating diseases: role of proteolytic enzymes, Crit. Rev. Neurobiol., 16 (1992) 257-271.
10. Banik, N.L., Fischer, I., Hogan, E.L. and Lobo, D., Calpain activity in spinal cord injury, J. Neurochem., 61 (1993) S112B.
11. Banik, N.L., Lobo, D., Terry, E.T. and Hogan, E.L., Inhibition of calpain by methylprednisolone (MP), Trans. Am. Soc. Neurochem., 25 (1994) 310.
12. Bartus, R., Baker, K.L., Keiser, A.D., Sawyer, S.D., Dean, R.L., Elliott, P.J. and Straub, J.A., Post-ischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage, J. Cereb. Blood Flow Metab., 14 (1994) 537-544.
13. Beck, R., Cleary, P.A., Trobe, J.D., Kaufman, D.I., Kupersmith, M.J., Paty, D.W. and Hendricks-Brown, C., The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis, NEJM, 329 (1993) 1764-1769.
14. Bloomgren, K., Kawashima, S., Saido, T.C., Karlsson, J.O., Elmered, A. and Hagberg, H., Fodrin degradation and subcellular distribution of calpain after neonatal rat cerebral hypoxic-ischemia, Brain Res., 684 (1995) 143-149.
15. Boheme, D.H., Umezawa, H., Hashim, G. and Marks, N., Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin), Neurochem. Res., 3 (1978) 185-194.
16. Bracken, M.B., Shepard, M.J., Collins, W.F., Holford, T.R., Young, W., Baskin, D.S., Eisenberg, H.M., Flamm, E., Leo-Summers, L., Maroon, J., Marshall, L.F., Perot, P.L., Piepmeier, J., Sonntag, V.K., Wagner, F.C. and Winn, H.R., A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury, NEJM, 322 (1990) 1405-1411.
17. Braughler, J.M. and Hall, E.D., Effects of multidose methylprednisolone sodium succinate administration of injured cat spinal cord neurofilament degradation and energy metabolism, J. Neurosurg., 61 (1984) 290-295.
18. Brosnan, C.F., Cammer, W., Norton, W.T. and Bloom, B.R., Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis, Nature, 285 (1980) 235-237.
19. Brostoff, S.W., Immunological responses to myelin and myelin components. In P. Morell (Ed.), Myelin, Plenum Press, New York, 1985, pp. 405-439.
20. Chakrabarti, A.K., Banik, N.L., Lobo, D., Terry, E.T. and Hogan, E.L., Calcium-activated neutral proteinase (calpain) in rat brain during development: compartmentation and role in myelination, Dev. Brain Res., 71 (1992) 107-113.
21. Choi, D.W., Glutamate neurotoxicity and diseases of the nervous system, Neuron, 1 (1988) 623-634.
22. Crawford, C., Protein and peptide inhibitors of calpain. In R.L. Mellgren and T. Murachi (Eds.), Intracellular Calcium Dependent Proteolysis, CRC Press, Boca Raton, 1990, pp. 75-89.
23. Croall, D. and DeMartino, G., Calcium-activated neutral proteinase (calpain) system: structure, function and regulation, Physiol. Rev., 71 (1991) 813-847.
24. Deshpande, R.V., Goust, J.M. and Banik, N.L., Differential distribution of calpain in human lymphoid cells, Neurochem. Res., 18 (1993) 77-773.
25. Hall, E.D., The neuroprotective pharmacology of methylprednisolone, J. Neurosurg., 76 (1991) 13-22.
26. ++ accumulation in experimental spinal cord trauma, Brain Res., 211 (1981) 476-479.
27. Hogan, E.L., Banik, N.L., Goust, J.M. and Lobo, D., Enzymes in cerebrospinal fluid: evidence for a calcium-activated neutral proteinase in CSF. In Llowenthal, A. and Raus, J. (Eds), Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis, Ser. A, Vol. 129, Plenum Publishing Corp., 1987, pp. 479-487.
28. Hogan, E.L. and Banik, N.L., Biochemistry of the spinal cord. In Lajtha, A. (Ed.), Handbook of Neurochemistry, Vol. 10, Plenum Press, New York, 1985, pp. 285-337.
29. Inuzuka, T., Sato, S., Baba, H. and Miyatake, T., Degradation of myelin basic protein in myelin by cerebrospinal fluid and effect of protease inhibitors, Acta Neuro. Scan., 76 (1987) 18-23.
30. Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of Bacteriophage T, Nature, 227 (1970) 680-685.
31. Lee, K.S., Frank, S., Vanderlisk, P., Arai, A. and Lynch, G., Inhibition of proteolysis protects hippocampal neurons from ischemia, Proc. Natl. Acad. Sci. USA., 88 (1990) 7233-7237.
32. Li, Z. and Banik, N.L., The localization of mcalpain in myelin: immunocytochemical evidence in different areas of rat brain and nerve, Brain Res., 697 (1995) 112-121.
33. Li, Z., Hogan, E.L. and Banik, N.L., Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat, Neurochem. Int., 27 (1995) 425-432.
34. 2 protein by a purified brain multicatalytic proteinase (MPC), Neurochem. Res., 17 (1992) 1261-1266.
35. Nixon, R.A., Saitoh, K.I., Catalso, A.M., Hamos, J., Hamilton, D., Honda, T. and Pope, A., Abnormalities of the calpain-calpastatin system in Alzheimer brain, Soc. Neurosci., 18 (1992) 198.
36. Ostwald, K., Hagberg, H., Andme, P. and Karlsson, J.O., Up-regulation of calpain activity in neonatal rat brain after hypoxic ischemia, Brain Res., 630 (1993) 289-294.
37. Posmantur, R., Hayes, R.L., Dixon, C.E. and Taft, W.C., Neurofilament 68 and neurofilament 200 protein levels after traumatic brain injury, J. Neurotrauma, 11 (1994) 533-545.
38. Rothman, S.M. and Olney, J.W., Excitotoxicity and the NMDA receptor, Trends Neurosci., 10 (1987) 299-302.
39. Sato, S., Quarles, R.H., Brady, R.O. and Tourtellotte, W.W., Elevated neutral proteinase activity in myelin from multiple sclerosis brain, Ann. Neurol., 15 (1984) 264-267.
40. Siman, R., Gall, C., Perlmutter, L.S., Christian, C., Baudry, M. and Lynch, G., Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain, Brain Res., 347 (1985) 399-403.
41. Smith, M.E., The role of proteolytic enzymes in experimental allergic encephalomyelitis, Neurochem. Res., 2 (1977) 223-246.
42. Smith, M.E., Proteinase inhibitors and the suppression of experimental allergic encephalomyelitis, In Davison, A.N. and Cuzner, M.L. (Eds.), The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis, Academic Press, London and New York, 1980, pp. 211-226.
43. Stokes, B., Fox, P. and Hollinden, G., Extracellular calcium activity in the injured spinal cord, Exp. Neurol., 80 (1983) 561-572.
44. Suzuki, K., Calcium activated neutral proteinase: domain structure and activity regulation, Trends Biochem. Sci., 12 (1987) 103-105.
45. Towbin, H., Stachlin, T. and Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, Proc. Natl. Acad. Sci. USA, 76 (1979) 4350-4354.
46. Tsujinaka, T., Kajiwana, Y., Kambayashi, J., Sakon, M., Higuchi, N., Tanaka, T. and Mori, T., Synthesis of new cell penetrating calpain inhibitor (calpeptin), Biochem. Biophys. Res. Commun., 153 (1988) 1201-1208.
47. Wilk, S. and Orlowski, M., Cation-sensitive endopeptidase: isolation and specificity of the bovine pituitary enzyme, J. Neurochem., 35 (1980) 1172-1182.
48. Young, W. and Flamm, E.S., Effect of high-dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal cord injury, J. Neurosurg., 57 (1982) 667-673.